Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Promoter Region
83%
Malignant Neoplasm
63%
Prognostic Factor
61%
Biological Marker
52%
Phlebothrombosis
50%
Overall Survival
45%
Cell-Free DNA
40%
Upper Gastrointestinal Cancer
38%
Venous Thromboembolism
38%
Preoperative Chemotherapy
37%
Pancreas Cancer
30%
Secreted Frizzled-Related Protein 1
27%
Pulmonary Embolism
25%
Cancer Diagnosis
24%
Neoadjuvant Therapy
23%
Neoplasm
22%
Postoperative Complication
22%
Plummer-Vinson Syndrome
22%
Deep Vein Thrombosis
20%
Radiation Therapy
20%
Prevalence
20%
Odds Ratio
19%
D-Dimer
19%
Esophageal Cancer
19%
Stomach Cancer
19%
Prospective Cohort Study
19%
Gemcitabine
18%
Adenocarcinoma
18%
microRNA
16%
Randomized Controlled Trial
16%
Cholangiocarcinoma
16%
Barrett Esophagus
16%
Cholelithiasis
16%
Prospective Study
16%
Monocyte
16%
Retrospective Study
16%
Leukocyte Activation
16%
Embolization
16%
Peptic Ulcer Bleeding
16%
Allele
16%
Esophageal Adenocarcinoma
16%
Chemotherapy
16%
Local Excision
16%
Computer Assisted Tomography
15%
Diseases
15%
Neoadjuvant Chemotherapy
14%
Oxaliplatin
13%
Pulmonary Angiography
13%
Recurrent Disease
13%
Keyphrases
Promoter Methylation
50%
SFRP1
50%
Pancreatic Adenocarcinoma
35%
Blood Biomarkers
22%
Gemcitabine
18%
Pancreatic Ductal Adenocarcinoma
18%
Cell-free DNA (cfDNA)
17%
Prognostic Marker
16%
DNA Promoter Hypermethylation
16%
Gastrointestinal Cancer Patients
16%
Neutrophil Activation Marker
16%
Arteria Lusoria
16%
Distal Cholangiocarcinoma
16%
Clinical Target Volume
16%
Endoscopic Surveillance
16%
Surgical Societies
16%
Gastroesophageal Junction Cancer
16%
Preoperative Surgery
16%
Gastroesophageal Adenocarcinoma
16%
Upper Gastrointestinal Cancer
16%
Preoperative Chemotherapy
16%
Cancer Outcomes
16%
Pancreaticobiliary Tract
16%
Cancer Prognostics
16%
Allele Fraction
16%
Metastatic Pancreatic Ductal Adenocarcinoma
16%
Prognostic Biomarker
16%
Total Neoadjuvant Therapy
16%
Perioperative Chemotherapy
16%
Gastroesophageal Junction
12%
Downstaging
12%
Total Neoadjuvant Treatment
12%
Cox Regression
11%
Absolute Monocyte Count
9%
Plasma microRNA
8%
Geometric Margin
8%
Gross Tumor Volume
8%
Radiotherapy Plan
8%
Junctional Adenocarcinoma
8%
Median Progression-free Survival
8%
Treatment of Recurrence
8%
Anatomic Site
8%
Treatment Characteristics
8%
Bisulfite Treatment
7%
Log-rank Test
7%
Promoter Region
7%
Median Overall Survival
7%
Rebleeding Rate
6%
Absolute Risk Difference
5%
Validation Studies
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
100%
Biological Marker
52%
Secreted Frizzled Related Protein 1
44%
Vein Thrombosis
33%
Chemotherapy
33%
Overall Survival
29%
Pancreas Cancer
27%
Gemcitabine
25%
Disease
19%
Prospective Cohort Study
16%
D Dimer
16%
microRNA
16%
Digestive System Cancer
16%
Cholelithiasis
16%
Randomized Controlled Trial
16%
Bile Duct Carcinoma
16%
Esophageal Adenocarcinoma
16%
Malignant Neoplasm
15%
Bisulfite
13%
Progression Free Survival
8%
Survival Time
8%
Second Cancer
8%
Recurrent Disease
8%
Randomized Clinical Trial
8%
Comorbidity
8%
Common Bile Duct Stone
6%
Calgranulin
5%
Cancer Staging
5%
Neoplasm
5%
